| Literature DB >> 35451384 |
Yuan Cao1, Pu Ning1, Qiao Li2, Shuang Wu2.
Abstract
OBJECTIVE: The relationship between cancers and obstructive sleep apnea (OSA) has been discussed for decades. However, the previous meta-analysis led to opposite conclusions. To further investigate this controversial issue, we performed this systematic review and meta-analysis update.Entities:
Mesh:
Year: 2022 PMID: 35451384 PMCID: PMC8913079 DOI: 10.1097/MD.0000000000028930
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Characteristics of the included studies.
| Author | Year | Country | Development | Population | Study design | Age | Gender | BMI | AHI | Diagnostic methods of OSA | Follow-up | Cancer | NOS |
| Gao | 2020 | China | Developing | 2400 | Mendelian randomization study | – | All women | OSA: case 23.97 ± 3.21, control 23.88 ± 3.17; breast cancer: case 23.96 ± 3.20, control 23.90 ± 3.24 | – | PSG | – | Breast cancer | 7 |
| Chen | 2019 | China | Developing | 20,900 | Cohort study | OSA: 45.97 yr, control: 45.64 yrs | OSA: men 2970, women 1210, control: men 11,880, women 4840 | – | – | ICD-9 | 14 yr | Colorectal cancer | 7 |
| Choi | 2019 | Korea | Developed | 274,201 | Retrospective cohort study | OSA: 48.7 ± 14.2; control: 48.7 ± 14.2 | All women | – | – | ICD-10 | 3.7 ± 2.3 yr | Breast cancer | 6 |
| Jara | 2019 | United States | Developed | 1,377,285 | Retrospective matched cohort | 55.2 ± 13.0 | Men 1,294,648, women 82,637 | – | – | ICD-9 | 8.1 ± 4.3 yr | Cancers | 7 |
| Liu | 2019 | China | Developing | 45 | Case-control study | – | – | – | – | PSG | 1 yr | Lung cancer | 6 |
| Polonis | 2019 | United States | Developed | 161 | Cohort study | Non-OSA: 35.6 ± 11.0, OSA: 47.3 ± 11.9 | Non-OSA: men 59, women 29; OSA: men 64, women 9 | Non-OSA: 26.9 ± 5.1; OSA: 33.0 ± | Non-OSA: 1.0 ± 1.3; OSA: 33.9 ± 27.3 | PSG | 12.7 yr | Cancers | 6 |
| Sillah | 2019 | United States | Developed | 1446 | Case-cohort study | Case group: 57.2 ± 10.8; subcohort: 50.4 ± 12.9 | Case group: men 173, women 131; subcohort: men 665, women 497 | – | Case group: 47.0 ± 31.1; subcohort: 41.3 ± 34.7 | PSG | 1851 (IQR: 1002–2835) d | Cancers | 8 |
| Brenner | 2018 | Israel | Developed | 5243 | Retrospective cohort study | 51 ± 13.1 | Men 3905, women 1338 | 29.7 (26.4–33.9) | 18 (10–34) | PSG | 5.9 yr | Cancers | 7 |
| Cabezas | 2018 | Spain | Developed | 60 | Cross-sectional study | 67.8 ± 11 | Men 35, women 25 | – | 15.2 (6.9–29.4) | PSG | 12 mo | Lung cancer | 6 |
| Campos-Rodriguez | 2018 | United States | Developed | 83 | Cross-sectional study | 48.8 ± 8.8 | All women | 27.4 ± 5.4 | 5.1 (2–9.4) | PSG | – | Breast cancer | 6 |
| Dreher | 2018 | Germany | Developed | 100 | Cross-sectional study | 68.1 ± 8.6 | Men 67, women 33 | 26.0 ± 4.6 | 4.9 (2.0,10.4) | PSG | – | Lung cancer | 6 |
| Du | 2018 | China | Developing | 10,388 | Cross-sectional study | 46.6 ± 0.4 | Men 5034, women 5354 | - | – | Self-reported | – | Cancers | 6 |
| Martinez-Garcia | 2018 | Spain | Developed | 443 | Cross-sectional study | 55.98 ± 15.3 | Men 224, women 219 | 27.3 ± 4.5 | 8.6 (2.8–20.2) | PSG | – | Melanoma | 6 |
| Gozal | 2016 | United States | Developed | 30.3 million | Cohort study | >30 yr | – | – | – | ICD-9 | 3 yr | Cancers | 6 |
| Lee | 2016 | Korea | Developed | 163 | Case-control study | OSA: 63.0 ± 10.9, non-OSA: 54.9 ± 14.5 | OSA: men 32, women 79; non-OSA: men 32, women 20 | OSA: 25.4 ± 3.3, non-OSA: 24.5 ± 3.3 | – | PSG | – | Colorectal neoplasia | 6 |
| Chang | 2014 | China | Developing | 5076 | Matched case-controlled study | – | All women | – | – | ICD-9 | 5 yr | Breast cancer | 6 |
| Chen | 2014 | China | Developing | 92,220 | Cohort study | OSA: 37.6 ± 8.2, control: 37.6 ± 8.2 | OSA: men 15,401, women 7654; control: men 46,202, women 22,963 | – | – | PSG | 10 yr | Primary central nervous system cancers | 7 |
| Kendzerska | 2014 | Canada | Developed | 10,149 | Cohort study | 48 (39–58) | Men 6284, women 3865 | 28.9 (25.3–33.4) | – | PSG | 7.8 yr | Cancers | 7 |
| Marshall | 2014 | Australia | Developed | 393 | Prospective cohort study | Non-OSA: 52.8 ± 7.6, mild OSA: 54.7 ± 7.3, moderate-severe OSA: 55.1 ± 8.2 | Men 290, women 103 | Non-OSA: 26.2 ± 3.7, mild OSA: 28.0 ± 4.0, moderate-severe OSA: 34.3 ± 7.3 | – | 4-channel portable home-monitoring device | 20 yr | Cancers | 8 |
| Martinez-Garcia | 2014 | Spain | Developed | 5427 | Retrospective cohort study | 53.9 ± 13.1 median (IQR) | – | – | 30 (14–52) | PSG | 4.5 yr | Cancers | 6 |
| Campos-Rodriguez | 2013 | Spain | Developed | 4910 | Retrospective cohort study | – | – | – | – | PSG or validated respiratory polygraphy (RP) | 4.5 (interquartile range, 3.4–5.2) yr | Cancers | 7 |
| Thompson | 2011 | United States | Developed | 1240 | Case-control study | Case group: 57.3 ± 8.0; control: 54.7 ± 8.8 | Case group: men 154, women 184; control: men 293, women 605 | Case group: 29.9 ± 7.2; control: 29.2 ± 6.8 | – | PSQI | – | Colorectal adenoma | 6 |
ICD = International classification of diseases, OSA = obstructive sleep apnea, PSG = polysomnography, PSQI = Pittsburgh sleep quality index.
Figure 1The overall prevalence of OSA positivity in cancer patients. OSA = obstructive sleep apnea.
Figure 2The overall prevalence of cancers in OSA patients vs non-OSA patients. OSA = obstructive sleep apnea.
Figure 3The cancer incidence in OSA patients subgroup by severity of OSA. OSA = obstructive sleep apnea.